Skip to main content

Advertisement

SpringerLink
Log in

Predicting survival of patients with metastatic renal cell carcinoma

  • Main topic
  • Published:
Der Urologe Aims and scope Submit manuscript

Abstract

The relationship between pretreatment clinical features and survival was studied from patients treated on clinical trials for metastatic renal cell carcinoma (RCC) at the Memorial Sloan-Kettering Cancer Center. The primary analysis was performed on 670 patients treated with cytokines or chemotherapy, from which a multivariate model was derived to predict survival. Studies which followed addressed: (1) the survival of patients given interferon-α as first-line therapy; (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy; and (3) survival of patients with non-clear cell histology. Prospective identification of patients more likely to benefit from cytokine therapy is important as a stratification factor in phase III trials, and in risk-directed therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Motzer RJ, Mazumdar M, Bacik J et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    CAS  PubMed  Google Scholar 

  2. Motzer RJ, Mazumdar M, Bacik J et al. (2000) Effect of cytokine therapy an survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928–1935

    CAS  PubMed  Google Scholar 

  3. Motzer R, Bacik J, Murphy BA et al. (2002) Interferon alfa as a comparative treatment for clinical trials of new therapies against renal cell carcinoma. J Clin Oncol 20:289–296

    Article  CAS  PubMed  Google Scholar 

  4. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V (2002) Treatment outcome and survival associated with metmtatic renal Gell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376–81

    Article  PubMed  Google Scholar 

Download references

Conflict of interest:

No information supplied

Author information

Authors and Affiliations

  1. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine and Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA

    R. J. Motzer & M. Mazumdar

  2. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine and Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

    R. J. Motzer

Authors
  1. R. J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Mazumdar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. J. Motzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Motzer, R.J., Mazumdar, M. Predicting survival of patients with metastatic renal cell carcinoma. Urologe 43 (Suppl 3), 135–136 (2004). https://doi.org/10.1007/s00120-004-0602-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-004-0602-x

Keywords

Search

Navigation